病例系列:在疱疹预防期间接种COVID-19 mRNA疫苗后疱疹性角膜炎的再激活

IF 1.8 Q2 Medicine
Michael Tsatsos, Efthymia Prousali, Athanasios Karamitsos, Nikolaos Ziakas
{"title":"病例系列:在疱疹预防期间接种COVID-19 mRNA疫苗后疱疹性角膜炎的再激活","authors":"Michael Tsatsos, Efthymia Prousali, Athanasios Karamitsos, Nikolaos Ziakas","doi":"10.3390/vision9030063","DOIUrl":null,"url":null,"abstract":"<p><p>This report presents two cases of herpes simplex keratitis recurrence after COVID-19 mRNA vaccination in patients on herpetic prophylaxis due to recurrent herpetic keratitis. A 58-year-old man with a history of a previous penetrating keratoplasty presented with blurred vision and evidence of corneal endothelitis 48 h after the first dose of the m-RNA vaccination, and a 24-year-old male student came with a dendritic ulcer 72 h post first vaccination dose. The original prophylactic treatment of 400 mg of acyclovir twice daily was increased to five times per day for a week for both patients. The grafted patient additionally received an increase in Dexamethasone 0.1% from twice daily to four times a day. Improvement was noted within two days and documented at the weekly review, during which both patients returned to their prophylactic antiviral regime without further recurrence. At the time of their second dose of vaccination, both patients followed the same regime with an increase in treatment as per the first dose of vaccination without recurrence. Our findings suggest that patients with recurrent herpetic disease receiving prophylactic treatment need close monitoring when experiencing even subtle symptoms of recurrence and may benefit from an increase in their dose to therapeutic levels during the first days after the COVID-19 mRNA vaccination.</p>","PeriodicalId":36586,"journal":{"name":"Vision (Switzerland)","volume":"9 3","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12372037/pdf/","citationCount":"0","resultStr":"{\"title\":\"Case Series: Reactivation of Herpetic Keratitis After COVID-19 mRNA Vaccination During Herpetic Prophylaxis.\",\"authors\":\"Michael Tsatsos, Efthymia Prousali, Athanasios Karamitsos, Nikolaos Ziakas\",\"doi\":\"10.3390/vision9030063\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This report presents two cases of herpes simplex keratitis recurrence after COVID-19 mRNA vaccination in patients on herpetic prophylaxis due to recurrent herpetic keratitis. A 58-year-old man with a history of a previous penetrating keratoplasty presented with blurred vision and evidence of corneal endothelitis 48 h after the first dose of the m-RNA vaccination, and a 24-year-old male student came with a dendritic ulcer 72 h post first vaccination dose. The original prophylactic treatment of 400 mg of acyclovir twice daily was increased to five times per day for a week for both patients. The grafted patient additionally received an increase in Dexamethasone 0.1% from twice daily to four times a day. Improvement was noted within two days and documented at the weekly review, during which both patients returned to their prophylactic antiviral regime without further recurrence. At the time of their second dose of vaccination, both patients followed the same regime with an increase in treatment as per the first dose of vaccination without recurrence. Our findings suggest that patients with recurrent herpetic disease receiving prophylactic treatment need close monitoring when experiencing even subtle symptoms of recurrence and may benefit from an increase in their dose to therapeutic levels during the first days after the COVID-19 mRNA vaccination.</p>\",\"PeriodicalId\":36586,\"journal\":{\"name\":\"Vision (Switzerland)\",\"volume\":\"9 3\",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-07-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12372037/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vision (Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/vision9030063\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vision (Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/vision9030063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

本文报道2例单纯疱疹性角膜炎患者在接种COVID-19 mRNA疫苗后因复发性疱疹性角膜炎接受疱疹预防后复发的病例。一名有穿透性角膜移植术史的58岁男性在第一次接种m-RNA疫苗48小时后出现视力模糊和角膜内皮炎的迹象,一名24岁的男学生在第一次接种疫苗72小时后出现树突状溃疡。两名患者最初的预防性治疗为每天两次400毫克阿昔洛韦,增加到每天5次,持续一周。此外,移植患者的地塞米松剂量增加0.1%,从每天2次增加到每天4次。改善在两天内被注意到,并记录在每周复查中,在此期间,两名患者都恢复到预防性抗病毒治疗方案,没有进一步复发。在进行第二剂疫苗接种时,两名患者都遵循相同的方案,并根据第一剂疫苗接种增加治疗,没有复发。我们的研究结果表明,接受预防性治疗的复发性疱疹疾病患者即使出现轻微的复发症状,也需要密切监测,并且在接种COVID-19 mRNA疫苗后的头几天将剂量增加到治疗水平可能会受益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Case Series: Reactivation of Herpetic Keratitis After COVID-19 mRNA Vaccination During Herpetic Prophylaxis.

Case Series: Reactivation of Herpetic Keratitis After COVID-19 mRNA Vaccination During Herpetic Prophylaxis.

Case Series: Reactivation of Herpetic Keratitis After COVID-19 mRNA Vaccination During Herpetic Prophylaxis.

Case Series: Reactivation of Herpetic Keratitis After COVID-19 mRNA Vaccination During Herpetic Prophylaxis.

This report presents two cases of herpes simplex keratitis recurrence after COVID-19 mRNA vaccination in patients on herpetic prophylaxis due to recurrent herpetic keratitis. A 58-year-old man with a history of a previous penetrating keratoplasty presented with blurred vision and evidence of corneal endothelitis 48 h after the first dose of the m-RNA vaccination, and a 24-year-old male student came with a dendritic ulcer 72 h post first vaccination dose. The original prophylactic treatment of 400 mg of acyclovir twice daily was increased to five times per day for a week for both patients. The grafted patient additionally received an increase in Dexamethasone 0.1% from twice daily to four times a day. Improvement was noted within two days and documented at the weekly review, during which both patients returned to their prophylactic antiviral regime without further recurrence. At the time of their second dose of vaccination, both patients followed the same regime with an increase in treatment as per the first dose of vaccination without recurrence. Our findings suggest that patients with recurrent herpetic disease receiving prophylactic treatment need close monitoring when experiencing even subtle symptoms of recurrence and may benefit from an increase in their dose to therapeutic levels during the first days after the COVID-19 mRNA vaccination.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Vision (Switzerland)
Vision (Switzerland) Health Professions-Optometry
CiteScore
2.30
自引率
0.00%
发文量
62
审稿时长
11 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信